GLP1R and coronary artery disorder: A genetic variant in GLP1R that mimics the glycemic effects of the Food and Drug Administration (FDA)-approved antidiabetic glucagon-like peptide-1 receptor agonists27 has also been shown to reduce coronary heart disease risk28.